Professor Hendrik Bonnemeier

Back

Professor Hendrik Bonnemeier

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)

Presentations

Renal function worsening in factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 1

Access

Are there shock incidence and mortality differences in primary prevention patients regarding device type and ischemia? A NORDIC ICD sub-study.

Event: ESC Congress 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Heart failure devices: new approaches

Access

Comparative effcomparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 4

Access

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 6

Access

State of the art in cardiac resynchronization therapy: how device features improve clinical outcomes

Event: ESC Congress 2019

Topic: Cardiac Resynchronisation Therapy (CRT)

Session: Heart failure in 2019: latest update on implantable device therapy

Access

Think about the kidneys: why does renal function matter in patients with atrial fibrillation?

Event: ESC Congress 2019

Topic: Stroke Prevention

Session: The bigger picture in stroke prevention and anticoagulation: think beyond atrial fibrillation

Access

Q&A and closing - Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together.

Event: Heart Failure 2019

Topic: Cardiovascular Disease in Special Populations

Session: Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together

Access

Interlinked factors affecting stroke risk in your patients with AF.

Event: Heart Failure 2019

Topic: Atrial Fibrillation (AF)

Session: Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together

Access

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Access

Characteristics of 15mg od rivaroxaban patients from the RELOAD study

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Access

ESC 365 is supported by

Explore sponsored resources

Professor Hendrik Bonnemeier Follow

Contributor content

Renal function worsening in factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Are there shock incidence and mortality differences in primary prevention patients regarding device type and ischemia? A NORDIC ICD sub-study.

Comparative effcomparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

State of the art in cardiac resynchronization therapy: how device features improve clinical outcomes

Think about the kidneys: why does renal function matter in patients with atrial fibrillation?

Q&A and closing - Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together.

Interlinked factors affecting stroke risk in your patients with AF.

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Characteristics of 15mg od rivaroxaban patients from the RELOAD study

ESC 365 is supported by

Professor Hendrik Bonnemeier